The revenue increase was primarily driven by increased revenue in the company's biopharma services, clinical services, and discovery services divisions.
By analyzing EMRs and genomic data, Mendel Health believes its AI platform can identify patients for ongoing trials and help clinicians select treatments.
The firm missed analysts' expectations on both the top and bottom lines, despite a reported 20 percent increase in clinical services revenues during the quarter.
The firm said in an SEC document that it may from time to time offer common stock, preferred stock, warrants, and overallotment purchase rights and units.
The firm’s biopharma revenues increased 11 percent, while clinical service revenues grew 20 percent, and discovery service revenue increased 12 percent.
Cancer Genetics will help analyze biomarkers to identify response patient populations, as well as reflect the mechanism of action of Effector's eFT508.
The companies expect their cancer clinical trial matching system to be available to early-access partners in the second quarter.
Its CEO said the firm has a clear path to achieving profitability, and that a big-data and artificial intelligence initiative will further expand its margins.
The companies will develop biomarkers of response to Lantern's lead therapy candidates, including a potential liquid biopsy assay for its NSCLC drug Tavocept.
Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.
The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.
CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.
In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.